Both authors contributed equally to this manuscript.
Multiple sclerosis treatment and infectious issues: update 2013
Version of Record online: 4 FEB 2014
© 2013 British Society for Immunology
Clinical & Experimental Immunology
Volume 175, Issue 3, pages 425–438, March 2014
How to Cite
Winkelmann, A., Loebermann, M., Reisinger, E. C. and Zettl, U. K. (2014), Multiple sclerosis treatment and infectious issues: update 2013. Clinical & Experimental Immunology, 175: 425–438. doi: 10.1111/cei.12226
- Issue online: 4 FEB 2014
- Version of Record online: 4 FEB 2014
- Accepted manuscript online: 18 OCT 2013 03:41AM EST
- Manuscript Accepted: 14 OCT 2013
- disease-modifying treatment;
- multiple sclerosis;
- side effects
Immunomodulation and immunosuppression are generally linked to an increased risk of infection. In the growing field of new and potent drugs for multiple sclerosis (MS), we review the current data concerning infections and prevention of infectious diseases. This is of importance for recently licensed and future MS treatment options, but also for long-term established therapies for MS. Some of the disease-modifying therapies (DMT) go along with threats of specific severe infections or complications, which require a more intensive long-term monitoring and multi-disciplinary surveillance. We update the existing warning notices and infectious issues which have to be considered using drugs for multiple sclerosis.